Keywords: sepracor, improves, position, nasdaq-listed, specialist, development, single-isomerproducts
Sepracor improves position in 2002
Article | 10 February 2003
Nasdaq-listed Sepracor, a specialist in the development of single-isomerproducts such as Clarinex (desloratadine) has narrowed its losses in 2002. The New ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
